Concepedia

Publication | Open Access

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis

DOIFull Paper Access

57

Citations

22

References

2021

Year

María Trojano, Lluís Ramió‐Torrentà, Luigi ME Grimaldi, Catherine Lubetzki, Sven Schippling, Karleyton C. Evans, Zheng Ren, Kumar Kandadi Muralidharan, Stephanie Licata, Arie Gafson
Multiple Sclerosis Journal

Abstract

Natalizumab 300 mg subcutaneous Q4W was comparable to 300 mg intravenous Q4W dosing with respect to efficacy, pharmacokinetics/pharmacodynamics, and safety.

References

YearCitations

Page 1